477199-77-2

Basic information

• Product Name: 4-(Bromomethyl)-2-fluorobenzoicacid
• Synonyms: 4-(Bromomethyl)-2-fluorobenzoicacid
• CAS NO: 477199-77-2
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 477199-77-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(Bromomethyl)-2-fluorobenzoicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Bromomethyl)-2-fluorobenzoicacid(477199-77-2)
• EPA Substance Registry System: 4-(Bromomethyl)-2-fluorobenzoicacid(477199-77-2)

Safety Data

• Hazardous Substances Data: 477199-77-2(Hazardous Substances Data)

Upstream product

• 214554-18-4 2-fluoro-4-(hydroxymethyl)benzoic acid 
• 89-62-3 4-methyl-2-nitroaniline 
• 53078-85-6 2-bromo-5-methylaniline 
• 5326-34-1 4-Bromo-3-nitrotoluene 
• 7697-23-6 2-fluoro-4-methylbenzoic Acid 
• 452-74-4 4-bromo-3-fluorotoluene 
• 612-45-3 4-methyl-2-nitroacetanilide 

Downstream Products

• 85070-57-1 methyl 4-(bromomethyl)-2-fluoro-benzoate 
• 1436421-49-6 N-(4,5-dichloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluoro-4-((1,1-dioxothiomorpholin-4-yl)methyl)benzamide 
• 1436421-47-4 (S)-4-((1-amino-3-hydroxy-1-oxopropan-2-ylamino)methyl)-N-(4,5-dichloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide 
• 1436426-32-2 4-(bromomethyl)-N-(4,5-dichloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide 

Relevant articles and documents

CONDENSED-CYCLIC COMPOUND

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

HETEROCYCLIC COMPOUND

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the specifi

ENZYME INHIBITORS

This invention relates to enzyme inhibitors that are inhibitors of plasma kallikrein and to pharmaceutical compositions containing and the uses of, such inhibitors.Specifically, the invention relates to compounds of formula (I): Formula (I) and tautomers,stereoisomers, pharmaceutically acceptable salts and solvates thereof; wherein R1 to R15, and Q are as defined herein.

A two-aryl thio hydantoin derivatives and use thereof

The invention provides a novel diarylthiohydantoin derivative with the structure represented by formula I, and its application. In the formula, X is O or S; R1 and R2 can bee same to or different from each other, respectively represent hydrogen, a C1-6 alkyl group, a C1-6 alkoxy group, a C3-8 naphthenic base, and a C3-8 alkenyl group; R3 represents hydrogen, halogen atoms, a hydroxyl group, a cyano group and a nitro group; R4 and R5 can be same to or different from each other, and respectively represent hydrogen, halogen atoms, -C=(O)-N-(C1-4alkyl) and -(C1-4alkyl)-C(=O)-N-(C1-4 alkyl); and n is 1, 2, 3, or 4. The invention also relates to the application of the above compounds in excessive proliferative diseases.

HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS

The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I) : wherein each symbol is as described in the specification, salt thereof.

N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention provides a selection of compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds.

BORON-CONTAINING DIACYLHYDRAZINES

The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I wherein the variables are as defined herein.

HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS

The present invention provides heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3 djpyrimidines of Formula Ia or a pharmaceutically acceptable salt thereof; wherein: A is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-I4 cycloalkyl, C2-13 heterocycloalkyl, C6-14 aryl, C1-14 heteroaryl, C3-14 cycloalkyl-C1-4 alkyl, C2-13 heterocycloalkyl-C1-4 alkyl, C6-14 aryl-C1-4 alkyl, or C14 heteroaryl-C14 alkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-14 cycloalkyl, C2-13 heterocycloalkyl, C6-14 aryl, C1-14 heteroaryl, C3-14 cycloalkyl-C1-4 alkyl, C2-13 heterocycloalkyl-C1-4 alkyl, C6-14 aryl-C1-4 alkyl, and C1-14 heteroaryl-C1-4 alkyl are each optionally substituted with I, 2, 3, 4, 5, or 6 independently selected R8 substituents; L is absent, C(=O), C(=O)NH, S(=O), or S(O)2; X is CH or N; Y is H, cyano, halo, C1-4 alkyl, or C1-4 haloalkyl; Z is CR7 or N; R1, R2, and R3 are each independently H, hydroxyl, halo, C1-3 alkyl, or C1-3 haloalkyl; R4 and R5 are each independently H, C1-3 alkyl, or C1-3 haloalkyl; or R4 and R5 together with the carbon atom to which they are attached can form a 3-, 4-, 5-, 6- υr 7-membered cycloalkyl ring; as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example inflammatory disorders, autoimmune disorders, cancer, and other diseases.